未知生产厂商
Datopotamab deruxtecan is under investigation in clinical trial NCT04656652 (Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)). In the 2026 ESMO Clinical Practice Guideline for metastatic breast cancer, datopotamab deruxtecan is recommended for ER-positive/HER2-negative metastatic breast cancer after at least one prior chemotherapy line, and for germline BRCA1/2-wild-type, PD-L1-negative triple-negative breast cancer as a recommended option for most patients if available.
Datopotamab deruxtecan is under investigation in clinical trial NCT04656652 (Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)). In the 2026 ESMO Clinical Practice Guideline for metastatic breast cancer, datopotamab deruxtecan is recommended for ER-positive/HER2-negative metastatic breast cancer after at least one prior chemotherapy line, and for germline BRCA1/2-wild-type, PD-L1-negative triple-negative breast cancer as a recommended option for most patients if available.
Per 2026 ESMO Clinical Practice Guideline for metastatic breast cancer: (1) ER-positive/HER2-negative metastatic breast cancer — recommended after at least one prior line of chemotherapy; (2) Triple-negative breast cancer (germline BRCA1/2-wild-type, PD-L1-negative) — recommended for most patients if available, alongside sacituzumab govitecan as an alternative option.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
